Salix Pharmaceuticals, Ltd. today announced that the U.S. FDA has informed Wilmington Pharmaceuticals that the Prescription Drug User Fee Act action date for the New Drug Application for METOZOLV (metoclopramide) Orally Disintegrating Tablets has been extended three months to provide time for a full review of the submission.
the details can be read here.
No comments:
Post a Comment